The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: A cross-sectional and longitudinal study

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Sandoo, Aamer ^a,b   Kitas, George D ^a,b,c   Carroll, Douglas ^b   Veldhuijzen van Zanten, Jet JCS ^a,b  

^a DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADALIMUMAB; ANTI TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; GLYCERYL TRINITRATE; HYPOCHOLESTEROLEMIC AGENT; INFLIXIMAB; METHOTREXATE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL FUNCTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DILATATION; DISEASE ACTIVITY; FEMALE; HUMAN; INFLAMMATION; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; RHEUMATOID ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LASER-DOPPLER FLOWMETRY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS;

EID: 84861026736     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3847     Document Type: Article

References (53)

1. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:607-613.
2. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14. 10.1136/ard.2010.142133, 21109513.
3. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005, 7:1-24.
4. Gokce N, Keaney JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003, 41:1769-1775. 10.1016/S0735-1097(03)00333-4, 12767663.
5. Ghitescu L, Robert M. Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc Res Tech 2002, 57:381-389. 10.1002/jemt.10091, 12112444.
6. Hill CE, Phillips JK, Sandow SL. Heterogeneous control of blood flow amongst different vascular beds. Med Res Rev 2001, 21:1-60. 10.1002/1098-1128(200101)21:1<1::AID-MED1>3.0.CO;2-6, 11135298.
7. Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor for ischaemic heat disease [abstract]. Arthritis Rheum 2000, 43(suppl 9):S385.
8. Sandoo A, Carroll D, Metsios GS, Kitas GD, Veldhuijzen van Zanten JJ. The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2011, 13:R99. 10.1186/ar3374, 3218914, 21693023.
9. Sandoo A, Veldhuijzen van Zanten JJCS, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology 2011, 50:2125-39. 10.1093/rheumatology/ker275, 21926155.
10. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1780-1784.
11. Arosio E, De MS, Rigoni A, Prior M, Delva P, Lechi A. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 2007, 25:1273-1278. 10.1097/HJH.0b013e3280b0157e, 17563541.
12. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006, 24:309-312.
13. Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, Boumpas DT. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009, 38:6-10. 10.1080/03009740802363768, 18991190.
14. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637-1641. 10.1161/01.ATV.0000033516.73864.4E, 12377742.
15. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nevill AM, Jamurtas AZ, Koutedakis Y, Kitas GD. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol 2009, 28:439-444. 10.1007/s10067-008-1073-z, 19096748.
16. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, Fair JM, Fletcher GF, Goff D, Hayman LL, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone N, Wilterdink J, Winston M. Managing abnormal blood lipids: a collaborative approach. Circulation 2005, 112:3184-3209. 10.1161/CIRCULATIONAHA.105.169180, 16286609.
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
18. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, De BD, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003. 10.1016/S0195-668X(03)00114-3, 12788299.
19. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008, 336:1475-1482. 10.1136/bmj.39609.449676.25, 2440904, 18573856.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
21. Prevoo ML, Van't Hof MA, Kuper HH, Van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
22. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986, 25:206-209. 10.1093/rheumatology/25.2.206, 3708236.
23. Radikova Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocr Regul 2003, 37:189-194.
24. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410. 10.1210/jc.85.7.2402, 10902785.
25. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
26. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619. 10.1001/jama.297.6.611, 17299196.
27. Turner J, Belch JJ, Khan F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med 2008, 18:109-116. 10.1016/j.tcm.2008.02.001, 18555183.
28. Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010, 4:302-312. 3040999, 21339899.
29. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
30. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963. 10.1161/01.CIR.0000099844.31524.05, 14676136.
31. Yki-Jarvinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003, 62:630-634. 10.1136/ard.62.7.630, 1754583, 12810424.
32. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, Csipo I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomjak E, Veres K, Szegedi G, Shoenfeld Y, Soltesz P. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008, 35:398-406.
33. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, Protogerou A, Panoulas VF, Sandoo A, Tentolouris N, Mavrikakis M, Sfikakis PP. Atherosclerosis in Rheumatoid Arthritis Versus Diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009, 29:1702-8. 10.1161/ATVBAHA.109.190108, 19608975.
34. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35. 10.1136/ard.2003.007740, 1754717, 14672888.
35. Pingiotti E, Cipriani P, Marrelli A, Liakouli V, Fratini S, Penco M, Giacomelli R. Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 2007, 1107:32-41. 10.1196/annals.1381.004, 17804530.
36. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007, 17:385-390. 10.1007/s10165-007-0605-8, 17929130.
37. Hansel S, Lassig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170:177-180. 10.1016/S0021-9150(03)00281-8, 12957697.
38. Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007, 192:391-395. 10.1016/j.atherosclerosis.2006.05.034, 16806231.
39. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-{alpha} treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187. 10.1161/01.CIR.0000037521.71373.44, 12390945.
40. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006, 26:1125-1131. 10.1007/s00296-006-0147-y, 16799778.
41. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450. 10.1002/art.20407, 15188332.
42. Bosello S, Santoliquido A, Zoli A, Di CC, Flore R, Tondi P, Ferraccioli G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008, 27:833-839. 10.1007/s10067-007-0803-y, 18075712.
43. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005, 111:363-368. 10.1161/01.CIR.0000153339.27064.14, 15668353.
44. Rojas-Villarraga A, Ortega-Hernandez OD, Gomez LF, Pardo AL, Lopez-Guzmen S, Rango-Ferreira C, Hincapie ME, Juan F, Pineda-Tamayo R, Diaz FJ, Anaya JM. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin Arthritis Rheum 2008, 38:71-82. 10.1016/j.semarthrit.2008.01.019, 18395773.
45. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, Huizinga TW, van de Stadt RJ, Dijkmans BA, van der LS. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:842-845. 10.1136/ard.62.9.842, 1754645, 12922956.
46. Stokes KY, Granger DN. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia?. J Physiol 2005, 562:647-653. 1665543, 15611017.
47. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2008, 38:366-71.
48. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol 1998, 32:123-127. 10.1016/S0735-1097(98)00206-X, 9669259.
49. Ghiadoni L, Magagna A, Kardasz I, Taddei S, Salvetti A. Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009, 22:506-512. 10.1038/ajh.2009.31, 19247267.
50. Yugar-Toledo JC, Ferreira-Melo SE, Consolim-Colombo FM, Irigoyen MC, Coelho OR, Moreno J. Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 2007, 16:315-321. 10.1016/j.niox.2006.12.004, 17276107.
51. Kojda G, Kottenberg K, Hacker A, Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm Acta Helv 1998, 73:27-35. 10.1016/S0031-6865(97)00044-7, 9708036.
52. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, Hajeer AH, Ollier WE, Mattey DL, Gonzalez-Gay MA. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003, 114:647-652. 10.1016/S0002-9343(03)00133-5, 12798452.
53. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Garcia-Bermudez M, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA. CCR5Delta32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 2011, 13:R133. 10.1186/ar3444, 3239375, 21846359.